The U.S. Food and Drug Administration has approved a key Eli Lilly and Co. (NYSE: LLY) diabetes treatment technology. The Indianapolis-based company says its Humalog KwikPen holds twice as much insulin as the current model. The technology was recommended for approval last summer by the European Medicines Agency. The European Union gave its approval in October.

The KwikPen is designed to help treat people with type 1 and type 2 diabetes. Lilly says the pen holds 600 units of insulin, versus the current model that holds 300 units.

Lilly Diabetes Vice President of Medical Affairs David Kendall says the technology will allow fewer pen changes per month, which he says will increase convenience for patients, especially those who use higher daily doses.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}